More importantly, pembrolizumab–axitinib combination benefits patients across the favorable, intermediate, and poor risk [International Metastatic RCC Database Consortium (IMDC) risk groups] instead of only PD-L1 expressive population (12). Here, CD274 is linked to renal cell carcinoma.